Biomed AI at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Biomed AI takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on AI-guided drug repurposing and AI analysis of anti-amyloid trial outcomes in support of a neurogenesis-based approach to Alzheimer's disease.

Organization	CTAD 2026 Attendance
BA Biomed AI San Jose, California
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Artificial Intelligence–Guided Drug Repurposing for Alzheimer’s Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases (P127) Digital assessment and AI · Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue AI-Enabled Analysis of Anti-Aβ Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer’s Disease (P128) Digital assessment and AI · Other mechanisms and targets

Organization

CTAD 2026 Attendance

Biomed AI

San Jose, California

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Artificial Intelligence–Guided Drug Repurposing for Alzheimer’s Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases (P127)

Digital assessment and AI · Other mechanisms and targets

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

AI-Enabled Analysis of Anti-Aβ Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer’s Disease (P128)

Digital assessment and AI · Other mechanisms and targets

Instantly find 20 buyers from Biomed AI

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction